Isoray Inc (ISR) 2.59 $ISR
Hot Stock: IsoRay, Shares Gain 10.7% (ISR)
Comtex SmarTrend(R) - Tue Aug 05, 10:08AM CDT
IsoRay (AMEX:ISR) is one of today's best performing low-priced stocks, up 10.7% to $2.64 on 1.0x average daily volume. IsoRay has traded 2.6 million shares thus far today, vs. average volume of 2.5 million shares per day. The stock has outperformed the Dow (10.5% to the Dow's -0.4%) and outperformed the S&P 500 (10.5% to the S&P's -0.4%) during today's trading.
IsoRay's Cesium-131 Isotope Produces Excellent Results in Treating Metastatic Brain Cancer as Published in the Journal of Neurosurgery
Marketwire - Tue Aug 05, 7:32AM CDT
IsoRay Inc. (NYSE MKT: ISR), a medical technology company and innovator in seed brachytherapy and medical radioisotope applications, today announced the publication of the first major peer reviewed study showing superior results using IsoRay's Cesium-131 seeds in the treatment of metastatic brain cancer.
Market Momentum on Biotech Stocks -- IsoRay, Neurocrine Biosciences, OPKO Health, Orexigen Therapeutics, and Gilead Sciences
PR Newswire - Thu Jul 31, 7:40AM CDT
On Wednesday, July 30, 2014, the NASDAQ Composite ended at 4,462.90, up 0.45%, the Dow Jones Industrial Average finished the day 0.19% lower at 16,880.36, and the S&P 500 closed at 1,970.07, up 0.01%. During the session five out of ten sectors ended in positive. The S&P 500 Health Care Sector Index ended the day at 718.94, up 0.36%, and the index has advanced 2.05% in the last one month. Investor-Edge has initiated coverage on the following equities: IsoRay Inc. (NYSE MKT: ISR), Neurocrine Biosciences Inc. (NASDAQ: NBIX), OPKO Health Inc. (NYSE: OPK), Orexigen Therapeutics Inc. (NASDAQ: OREX), and Gilead Sciences Inc. (NASDAQ: GILD). Free research on these five companies can be accessed at:
Why IsoRay (ISR) Stock Is Spiking Today
at The Street - Mon Jul 14, 10:41AM CDT
IsoRay (ISR) shares are climbing after the company's Cesium-131 internal radiation seeds were used in the world's first successful stereotactic brain implant surgery.
IsoRay Makes First Cesium-131 Delivery for Treatment of an Inoperable Brain Cancer Afflicting a Young Child in Peru
Marketwire - Mon Jul 14, 7:30AM CDT
IsoRay Inc. (NYSE MKT: ISR), a medical technology company and innovator in seed brachytherapy and medical radioisotope applications, today announced the first Cesium-131 seed shipment to Peru for the treatment of a Glioma brain tumor located near the brainstem.
IsoRay Announces Its Addition to the Russell Microcap Index
Marketwire - Mon Jun 30, 7:45AM CDT
IsoRay, Inc. (NYSE MKT: ISR), a medical technology company and innovator in seed brachytherapy and medical radioisotope applications for cancers of the brain, lung, head and neck, prostate and gynecologic ("gyn"
, today announced that it has been added to the Russell Microcap Index.
A Beaten-Down Biotech Stock Gearing Up for a Big Squeeze Higher
at The Street - Tue Jun 24, 1:22PM CDT
The shorts are betting against this biotech stock, but its technical chart is telling a different story.
Traders Get Bullish on Shares of IsoRay, Shares Up 15.2% (ISR)
Comtex SmarTrend(R) - Tue Jun 24, 10:09AM CDT
IsoRay (AMEX:ISR) is one of today's best performing low-priced stocks, up 15.2% to $3.08 on 5.1x average daily volume. IsoRay has traded 9.9 million shares thus far today, vs. average volume of 1.9 million shares per day. The stock has outperformed the Dow (15.2% to the Dow's 0.1%) and outperformed the S&P 500 (15.2% to the S&P's 0.3%) during today's trading.
Why IsoRay (ISR) Stock Is Surging Today
at The Street - Tue Jun 24, 9:38AM CDT
IsoRay (ISR) surged Tuesday after the company announced the world's first liquid cesium-131 treatment for metastatic brain cancer.
IsoRay Announces World's First Liquid Cesium-131 (Cesitrex(R)) Treatment for Metastatic Brain Cancer Utilizing the GliaSite(R) Radiation Therapy Balloon Catheter System
Marketwire - Tue Jun 24, 7:45AM CDT
IsoRay, Inc. (NYSE MKT: ISR), a medical technology company and innovator in seed brachytherapy and medical radioisotope applications, today announced another milestone -- the treatment of a brain tumor that had metastasized from esophageal cancer utilizing IsoRay's liquid Cesium-131 (Cesitrex(R)) which recently was FDA cleared for internal radiation therapy.
Health Care Sector Stocks Technical Analysis -- Research on United Therapeutics, IsoRay, Bruker, and Affymetrix
PR Newswire - Mon Jun 23, 6:50AM CDT
On Friday, June 20, 2014, the NASDAQ Composite ended at 4,368.04, up 0.20%, the Dow Jones Industrial Average finished the session at 16,947.08, up 0.15% and the S&P 500 closed at 1,962.87, up 0.17%. During the trading session, five out of ten sectors finished on a higher note. The S&P 500 Health Care Sector Index ended the day 0.84% higher at 702.66, and the index has advanced 3.99% in the previous three months. Investor-Edge has initiated coverage on the following equities: United Therapeutics Corp. (NASDAQ: UTHR), IsoRay Inc. (NYSE MKT: ISR), Bruker Corp. (NASDAQ: BRKR) and Affymetrix Inc. (NASDAQ: AFFX). Free technical research on UTHR, ISR, BRKR and AFFX can be downloaded upon signing up at:
IsoRay Announces New Russian and Peruvian International Distributor Agreements for the Sale of IsoRay's Full Line of Products
Marketwire - Fri Jun 20, 7:45AM CDT
IsoRay, Inc. (NYSE MKT: ISR) (http://www.isoray.com/), announced today that it has entered into two (2) international distribution agreements: the first with MedikorPharma-Ural LLC for the Russian market and the other with Surgicorp SRL for the Peruvian market. IsoRay is a medical technology company and innovator in seed brachytherapy and medical radioisotope applications for brain cancer, lung cancer, head and neck cancer, prostate cancer and gynecologic ("gyn" cancer.
5 Stocks Under $10 Set to Soar
at The Street - Thu Jun 05, 12:58PM CDT
These under-$10 stocks look ready to break out and trade higher from current levels.
Hot Stock: IsoRay, Shares Gain 22.3% (ISR)
Comtex SmarTrend(R) - Tue Apr 01, 10:10AM CDT
IsoRay (AMEX:ISR) is one of today's best performing low-priced stocks, up 22.3% to $2.69 on 1.4x average daily volume. IsoRay has traded 16.0 million shares thus far today, vs. average volume of 11.1 million shares per day. The stock has outperformed the Dow (22.3% to the Dow's 0.4%) and outperformed the S&P 500 (22.3% to the S&P's 0.4%) during today's trading.
Hot Stock: IsoRay, Shares Gain 10.7% (ISR)
Comtex SmarTrend(R) - Tue Aug 05, 10:08AM CDT
IsoRay (AMEX:ISR) is one of today's best performing low-priced stocks, up 10.7% to $2.64 on 1.0x average daily volume. IsoRay has traded 2.6 million shares thus far today, vs. average volume of 2.5 million shares per day. The stock has outperformed the Dow (10.5% to the Dow's -0.4%) and outperformed the S&P 500 (10.5% to the S&P's -0.4%) during today's trading.
IsoRay's Cesium-131 Isotope Produces Excellent Results in Treating Metastatic Brain Cancer as Published in the Journal of Neurosurgery
Marketwire - Tue Aug 05, 7:32AM CDT
IsoRay Inc. (NYSE MKT: ISR), a medical technology company and innovator in seed brachytherapy and medical radioisotope applications, today announced the publication of the first major peer reviewed study showing superior results using IsoRay's Cesium-131 seeds in the treatment of metastatic brain cancer.
Market Momentum on Biotech Stocks -- IsoRay, Neurocrine Biosciences, OPKO Health, Orexigen Therapeutics, and Gilead Sciences
PR Newswire - Thu Jul 31, 7:40AM CDT
On Wednesday, July 30, 2014, the NASDAQ Composite ended at 4,462.90, up 0.45%, the Dow Jones Industrial Average finished the day 0.19% lower at 16,880.36, and the S&P 500 closed at 1,970.07, up 0.01%. During the session five out of ten sectors ended in positive. The S&P 500 Health Care Sector Index ended the day at 718.94, up 0.36%, and the index has advanced 2.05% in the last one month. Investor-Edge has initiated coverage on the following equities: IsoRay Inc. (NYSE MKT: ISR), Neurocrine Biosciences Inc. (NASDAQ: NBIX), OPKO Health Inc. (NYSE: OPK), Orexigen Therapeutics Inc. (NASDAQ: OREX), and Gilead Sciences Inc. (NASDAQ: GILD). Free research on these five companies can be accessed at:
Why IsoRay (ISR) Stock Is Spiking Today
at The Street - Mon Jul 14, 10:41AM CDT
IsoRay (ISR) shares are climbing after the company's Cesium-131 internal radiation seeds were used in the world's first successful stereotactic brain implant surgery.
IsoRay Makes First Cesium-131 Delivery for Treatment of an Inoperable Brain Cancer Afflicting a Young Child in Peru
Marketwire - Mon Jul 14, 7:30AM CDT
IsoRay Inc. (NYSE MKT: ISR), a medical technology company and innovator in seed brachytherapy and medical radioisotope applications, today announced the first Cesium-131 seed shipment to Peru for the treatment of a Glioma brain tumor located near the brainstem.
IsoRay Announces Its Addition to the Russell Microcap Index
Marketwire - Mon Jun 30, 7:45AM CDT
IsoRay, Inc. (NYSE MKT: ISR), a medical technology company and innovator in seed brachytherapy and medical radioisotope applications for cancers of the brain, lung, head and neck, prostate and gynecologic ("gyn"
, today announced that it has been added to the Russell Microcap Index. A Beaten-Down Biotech Stock Gearing Up for a Big Squeeze Higher
at The Street - Tue Jun 24, 1:22PM CDT
The shorts are betting against this biotech stock, but its technical chart is telling a different story.
Traders Get Bullish on Shares of IsoRay, Shares Up 15.2% (ISR)
Comtex SmarTrend(R) - Tue Jun 24, 10:09AM CDT
IsoRay (AMEX:ISR) is one of today's best performing low-priced stocks, up 15.2% to $3.08 on 5.1x average daily volume. IsoRay has traded 9.9 million shares thus far today, vs. average volume of 1.9 million shares per day. The stock has outperformed the Dow (15.2% to the Dow's 0.1%) and outperformed the S&P 500 (15.2% to the S&P's 0.3%) during today's trading.
Why IsoRay (ISR) Stock Is Surging Today
at The Street - Tue Jun 24, 9:38AM CDT
IsoRay (ISR) surged Tuesday after the company announced the world's first liquid cesium-131 treatment for metastatic brain cancer.
IsoRay Announces World's First Liquid Cesium-131 (Cesitrex(R)) Treatment for Metastatic Brain Cancer Utilizing the GliaSite(R) Radiation Therapy Balloon Catheter System
Marketwire - Tue Jun 24, 7:45AM CDT
IsoRay, Inc. (NYSE MKT: ISR), a medical technology company and innovator in seed brachytherapy and medical radioisotope applications, today announced another milestone -- the treatment of a brain tumor that had metastasized from esophageal cancer utilizing IsoRay's liquid Cesium-131 (Cesitrex(R)) which recently was FDA cleared for internal radiation therapy.
Health Care Sector Stocks Technical Analysis -- Research on United Therapeutics, IsoRay, Bruker, and Affymetrix
PR Newswire - Mon Jun 23, 6:50AM CDT
On Friday, June 20, 2014, the NASDAQ Composite ended at 4,368.04, up 0.20%, the Dow Jones Industrial Average finished the session at 16,947.08, up 0.15% and the S&P 500 closed at 1,962.87, up 0.17%. During the trading session, five out of ten sectors finished on a higher note. The S&P 500 Health Care Sector Index ended the day 0.84% higher at 702.66, and the index has advanced 3.99% in the previous three months. Investor-Edge has initiated coverage on the following equities: United Therapeutics Corp. (NASDAQ: UTHR), IsoRay Inc. (NYSE MKT: ISR), Bruker Corp. (NASDAQ: BRKR) and Affymetrix Inc. (NASDAQ: AFFX). Free technical research on UTHR, ISR, BRKR and AFFX can be downloaded upon signing up at:
IsoRay Announces New Russian and Peruvian International Distributor Agreements for the Sale of IsoRay's Full Line of Products
Marketwire - Fri Jun 20, 7:45AM CDT
IsoRay, Inc. (NYSE MKT: ISR) (http://www.isoray.com/), announced today that it has entered into two (2) international distribution agreements: the first with MedikorPharma-Ural LLC for the Russian market and the other with Surgicorp SRL for the Peruvian market. IsoRay is a medical technology company and innovator in seed brachytherapy and medical radioisotope applications for brain cancer, lung cancer, head and neck cancer, prostate cancer and gynecologic ("gyn"
cancer. 5 Stocks Under $10 Set to Soar
at The Street - Thu Jun 05, 12:58PM CDT
These under-$10 stocks look ready to break out and trade higher from current levels.
Hot Stock: IsoRay, Shares Gain 22.3% (ISR)
Comtex SmarTrend(R) - Tue Apr 01, 10:10AM CDT
IsoRay (AMEX:ISR) is one of today's best performing low-priced stocks, up 22.3% to $2.69 on 1.4x average daily volume. IsoRay has traded 16.0 million shares thus far today, vs. average volume of 11.1 million shares per day. The stock has outperformed the Dow (22.3% to the Dow's 0.4%) and outperformed the S&P 500 (22.3% to the S&P's 0.4%) during today's trading.
